Company profile
MitoRx Therapeutics - First-in-class mitochondrial protective therapeutics
Developing revolutionary mitochondrial-protective therapeutics which reverse mitochondrial dysfunction to arrest decline in muscular dystrophy and neurodegeneration. Mito Rx Therapeutics' first-in-class first-in-target platform has potential to arrest the progression of some of the most challenging diseases.
Financial period: 1 Apr 2024 to 31 Mar 2025
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
RESOLUTIONS | Transaction WURGOFhYRU9hZGlxemtjeA | Paper/PDF filed
Published 19 Nov 2024 11:23
RESOLUTIONS | Transaction WURGOFhXVVphZGlxemtjeA | Paper/PDF filed
Published 19 Nov 2024 11:19
Company registered at Companies House
MitoRx Therapeutics develops mitochondrial treatments for rare neuromuscular disorders and metabolic disease.
Developing revolutionary mitochondrial-protective therapeutics Reversing mitochondrial dysfunction to arrest decline in muscular dystrophy and neurodegeneration
This a newly incorporated company, in which co-applicant (Prof Matt Whiteman) is the Chief Scientific Officer. They are developing a pipeline of novel compounds for application in a variety of disease areas (https://www.mitorxtherapeutics.com/).
N/A
Seed round over-subscribed (March 2022); seed extension December 2023; https://ukinnovationscienceseedfund.co.uk/mitorx-therapeutics-announces-close-of-seed-extension-financing-round-to-advance-its-mitochondrial-protective-therapeutics-to-treat-degenerative-diseases/; new patents filed. Further top up funding (7 figures) Q1 2025
